Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235176 | 0.85 | HRH3 (0.46) | HRH3 | |
| SCHEMBL17646031 | 0.82 | HRH3 (0.53) | HRH3SMN1; SMN2HIF1AEPAS1ALDH1A1 | |
| SCHEMBL29725196 | 0.81 | HRH3 (0.56) | HRH3SMN1; SMN2HIF1AEPAS1ALDH1A1 | |
| SCHEMBL115530 | 0.81 | DRD2 (0.56) | HRH3SMN1; SMN2HIF1AEPAS1ALDH1A1 | |
| SCHEMBL392141 | 0.81 | HRH3 (0.56) | HRH3SMN1; SMN2HIF1AEPAS1ALDH1A1 | |
| SCHEMBL23235216 | 0.81 | HRH3 (0.56) | HRH3SMN1; SMN2HIF1AEPAS1ALDH1A1 | |
| SCHEMBL1820769 | 0.81 | HRH3 (0.56) | HRH3SMN1; SMN2HIF1AEPAS1ALDH1A1 | |
| SCHEMBL1822660 | 0.81 | HRH3 (0.56) | HRH3SMN1; SMN2HIF1AEPAS1ALDH1A1 | |
| SCHEMBL392531 | 0.81 | HRH3 (0.61) | HRH3SMN1; SMN2HIF1AEPAS1MEN1 | |
| SCHEMBL2233359 | 0.81 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1MAPTNPC1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3141552-B1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM IND CO LTD (KR) | 2019-04-17 | — | — | EP | claimed |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2018-10-30 | — | — | US | claimed |
| EP-3141552-A1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2017-03-15 | — | — | EP | claimed |
| EP-2528920-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2012-12-05 | — | — | EP | claimed |
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-29 | — | — | US | claimed |
| US-8026243-B2 | [4,5′]Bipyrimidinyl-6,4′-diamine derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2011-09-27 | — | — | US | claimed |
| WO-2011093672-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2011-08-04 | — | — | WO | claimed |
| EP-2044036-B1 | [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2011-05-04 | — | — | EP | claimed |
| US-20100234376-A1 | [4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors | NOVARTIS AG | 2010-09-16 | — | — | US | claimed |
| EP-2044036-A1 | [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS | IRM, LLC (BM) | 2009-04-08 | — | — | EP | claimed |
| WO-2008008747-A1 | [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2008-01-17 | — | — | WO | claimed |
| EP-3141552-B1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM IND CO LTD (KR) | 2019-04-17 | — | — | EP | disclosed |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2018-10-30 | — | — | US | disclosed |
| EP-3141552-A1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2017-03-15 | — | — | EP | disclosed |
| EP-2528920-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2012-12-05 | — | — | EP | disclosed |
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-29 | — | — | US | disclosed |
| WO-2011093672-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | CDK2, SBK3, CDK2AP1 | HRH3 4112/4885SMN1; SMN2 3500/4885HIF1A 3614/4885 |
| US-20100234376-A1 | [4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors | FGFR3, ERBB2, ERBB4 | HRH3 3363/4885SMN1; SMN2 1670/4885HIF1A 1284/4885 |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | CDK2, SBK3, CDK2AP1 | HRH3 4112/4885SMN1; SMN2 3500/4885HIF1A 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.